Skip to main content
SpringerLink
Log in

Biomarkers in Psychiatry: Conceptual and Methodological Challenges

  • Chapter
  • First Online:
Biomarkers in Neuropsychiatry

  • 307 Accesses

Abstract

There are fundamental differences in the diagnostic process and the pathogenesis/pathophysiology of mental disorders compared to other clinical areas that pose a challenge to the discovery of biomarkers in psychiatry. As psychiatric disorders are symptomatically defined, it is unlikely that they represent biologically unitary categories and therefore debatable whether diagnostic biomarkers could meaningfully inform clinical diagnosis. The use of biomarkers for stratification, prognostication, and/or therapeutic decision is more promising, and they could map biotypes that can help reframe current diagnostic and treatment frameworks.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Teixeira AL, Salem H, Frey BN, Barbosa IG, Machado-Vieira R. Update on bipolar disorder biomarker candidates. Expert Rev Mol Diagn. 2016;16(11):1209–20.

    Article  CAS  PubMed  Google Scholar 

  2. Teixeira AL, Colpo GD, Fries GR, Bauer IE, Selvaraj S. Biomarkers for bipolar disorder: current status and challenges ahead. Expert Rev Neurother. 2019;19(1):67–81.

    Article  CAS  PubMed  Google Scholar 

  3. Elliott P, Cowie MR, Franke J, Ziegler A, Antoniades C, Bax J, et al. Development, validation, and implementation of biomarker testing in cardiovascular medicine state-of-the-art: proceedings of the European Society of Cardiology-Cardiovascular Round Table. Cardiovasc Res. 2021;117(5):1248–56.

    Article  CAS  PubMed  Google Scholar 

  4. Chan MK, Cooper JD, Bahn S. Commercialisation of biomarker tests for mental illnesses: advances and obstacles. Trends Biotechnol. 2015;33(12):712–23.

    Article  CAS  PubMed  Google Scholar 

  5. Korth C, Fangerau H. Blood tests to diagnose schizophrenia: self-imposed limits in psychiatry. Lancet Psychiatry. 2020;7(10):911–4.

    Article  PubMed  Google Scholar 

  6. Williams LM, Hack LM, American Psychiatric Association Publishing. Precision psychiatry: using neuroscience insights to inform personally tailored, measurement-based care. 1st ed. Washington, DC: American Psychiatric Association Publishing; 2022. xxvii, 264 p.

    Google Scholar 

  7. Kraus VB. Biomarkers as drug development tools: discovery, validation, qualification and use. Nat Rev Rheumatol. 2018;14(6):354–62.

    Article  CAS  PubMed  Google Scholar 

  8. Davis J, Maes M, Andreazza A, McGrath JJ, Tye SJ, Berk M. Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass. Mol Psychiatry. 2015;20(2):152–3.

    Article  CAS  PubMed  Google Scholar 

  9. Kim YK, Park SC. An alternative approach to future diagnostic standards for major depressive disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2021;105:110133.

    Article  Google Scholar 

  10. Hung YN, Yang SY, Kuo CJ, Lin SK. Diagnostic consistency and interchangeability of schizophrenic disorders and bipolar disorders: a 7-year follow-up study. Psychiatry Clin Neurosci. 2018;72(3):180–8.

    Article  PubMed  Google Scholar 

  11. Derks EM, Thorp JG, Gerring ZF. Ten challenges for clinical translation in psychiatric genetics. Nat Genet. 2022;54(10):1457–65.

    Article  CAS  PubMed  Google Scholar 

  12. Ikeda M, Saito T, Kanazawa T, Iwata N. Polygenic risk score as clinical utility in psychiatry: a clinical viewpoint. J Hum Genet. 2021;66(1):53–60.

    Article  PubMed  Google Scholar 

  13. Fernandes BS, Dai Y, Jia P, Zhao Z. Charting the proteome landscape in major psychiatric disorders: from biomarkers to biological pathways towards drug discovery. Eur Neuropsychopharmacol. 2022;61:43–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Smith M. Hyperactive around the world? The history of ADHD in global perspective. Soc Hist Med. 2017;30(4):767–87.

    PubMed  PubMed Central  Google Scholar 

  15. Xu G, Strathearn L, Liu B, Yang B, Bao W. Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among US children and adolescents, 1997–2016. JAMA Netw Open. 2018;1(4):e181471.

    Article  PubMed  PubMed Central  Google Scholar 

  16. WHO. [cited 2022 March 2nd]. Available from: https://www.who.int/news/item/02-03-2022-covid-19-pandemic-triggers-25-increase-in-prevalence-of-anxiety-and-depression-worldwide

  17. Dean OM, Walker AJ. Current approaches to precision medicine in psychiatry: are we just spinning our wheels? Eur Neuropsychopharmacol. 2023;66:11–3.

    Article  CAS  Google Scholar 

  18. Scarr E, Millan MJ, Bahn S, Bertolino A, Turck CW, Kapur S, et al. Biomarkers for psychiatry: the journey from fantasy to fact, a report of the 2013 CINP think tank. Int J Neuropsychopharmacol. 2015;18(10):pyv042.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Health NIoM. About RDoC. Available from: https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/about-rdoc

  20. Berk M. Biomarkers in psychiatric disorders: status quo, impediments and facilitators. World Psychiatry. 2023;22(2):174–6.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Abi-Dargham A, Moeller SJ, Ali F, DeLorenzo C, Domschke K, Horga G, et al. Candidate biomarkers in psychiatric disorders: state of the field. World Psychiatry. 2023;22(2):236–62.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov. 2003;2(7):566–80.

    Article  CAS  PubMed  Google Scholar 

  23. Abboud H, Probasco JC, Irani S, Ances B, Benavides DR, Bradshaw M, et al. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. 2021;92(7):757–68.

    Article  PubMed  Google Scholar 

  24. BEST (Biomarkers, endpoints, and other tools) resource [Internet] [Internet]. Silver Spring (MD): Food and Drug Administration (US); Bethesda (MD): National Institutes of Health (US). 2016. Available from: www.ncbi.nlm.nih.gov/books/NBK326791/

  25. Califf RM. Biomarker definitions and their applications. Exp Biol Med. 2018;243(3):213–21.

    Article  CAS  Google Scholar 

  26. Nadar PM, Merrill MA, Austin K, Strakowski SM, Halpern JM. The emergence of psychoanalytical electrochemistry: the translation of MDD biomarker discovery to diagnosis with electrochemical sensing. Transl Psychiatry. 2022;12(1):372.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA

    Antonio L. Teixeira

  2. Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX, USA

    Natalia P. Rocha

  3. IMPACT (The Institute for Mental and Physical Health and Clinical Translation), Deakin University, Geelong, VIC, Australia

    Michael Berk

  4. Orygen The National Centre of Excellence in Youth Mental Health, University of Melbourne, Parkville, VIC, Australia

    Michael Berk

  5. The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia

    Michael Berk

Authors
  1. Antonio L. Teixeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Natalia P. Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Berk
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Antonio L. Teixeira .

Editor information

Editors and Affiliations

  1. Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, The University of Texas Health Science Center at Houston, Houston, TX, USA

    Antonio L. Teixeira

  2. Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX, USA

    Natalia P. Rocha

  3. IMPACT (Institute for Innovation in Mental and Physical Health and Clinical Translation), Deakin University, Geelong, VIC, Australia

    Michael Berk

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Teixeira, A.L., Rocha, N.P., Berk, M. (2023). Biomarkers in Psychiatry: Conceptual and Methodological Challenges. In: Teixeira, A.L., Rocha, N.P., Berk, M. (eds) Biomarkers in Neuropsychiatry. Springer, Cham. https://doi.org/10.1007/978-3-031-43356-6_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-43356-6_20

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-43355-9

  • Online ISBN: 978-3-031-43356-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation